Literature DB >> 11485629

Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.

P M Joseph1, B P O'Sullivan, A Lapey, H Dorkin, J Oren, R Balfour, M A Perricone, M Rosenberg, S C Wadsworth, A E Smith, J A St George, D P Meeker.   

Abstract

Cystic fibrosis (CF), an autosomal recessive disorder resulting from mutations in the cystic fibrosis trans-membrane conductance regulator (CFTR) gene, is the most common lethal genetic illness in the Caucasian population. Gene transfer to airway epithelium, using adenoviruses containing normal CFTR cDNA, leads to transient production of CFTR mRNA and, in some studies, to correction of the airway epithelial ion transport defect caused by dysfunctional CFTR. Inflammatory responses to the adenoviral vector have been reported, particularly at high viral titers. We evaluated the effects of adenovirus-mediated CFTR gene transfer to airway epithelium in 36 subjects with CF (34 individuals, 2 of whom received two separate doses of vector), 20 by lobar instillation and 16 by aerosol administration. Doses ranged from 8 x 10(6) to 2.5 x 10(10) infective units (IU), in 0.5-log increments. After lobar administration of low doses there were occasional reports of cough, low-grade temperature, and myalgias. At the highest lobar dose (2.5 x 10(9) IU) two of three patients had transient myalgias, fever, and increased sputum production with obvious infiltrates on CT scan. After aerosol administration there were no significant systemic symptoms until the 2.5 x 10(10) IU dose, when both patients experienced myalgias and fever that resolved within 24 hr. There were no infiltrates seen on chest CT scans in any of the patients in the aerosol administration group. There were no consistent changes in pulmonary function tests or any significant rise in serum IgG or neutralizing antibodies in patients from either group. Serum, sputum, and nasal cytokines, measured before and after vector administration, showed no correlation with adenoviral dose. Gene transfer to lung cells was inefficient and expression was transient. Cells infected with the vector included mononuclear inflammatory cells as well as cuboidal and columnar epithelial cells. In summary, we found no consistent immune response, no evidence of viral shedding, and no consistent change in pulmonary function in response to adenovirus-mediated CFTR gene transfer. At higher doses there was a mild, nonspecific inflammatory response, as evidenced by fevers and myalgias. Overall, vector administration was tolerated but transfer of CFTR cDNA was inefficient and transgene expression was transient for the doses and method of administration used here.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485629     DOI: 10.1089/104303401750298535

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  23 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

Review 2.  Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.

Authors:  Nandini Sakurikar; Alan Eastman
Journal:  Cell Cycle       Date:  2016-03-17       Impact factor: 4.534

Review 3.  Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies.

Authors:  Cedric R Uytingco; Warren W Green; Jeffrey R Martens
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

Review 4.  RNAi therapeutic strategies for acute respiratory distress syndrome.

Authors:  Melissa L Jagrosse; David A Dean; Arshad Rahman; Bradley L Nilsson
Journal:  Transl Res       Date:  2019-07-27       Impact factor: 7.012

Review 5.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

Review 6.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

7.  Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia.

Authors:  David R Koehler; Umadevi Sajjan; Yu-Hua Chow; Bernard Martin; Geraldine Kent; A Keith Tanswell; Colin McKerlie; Janet F Forstner; Jim Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

8.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

9.  Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model.

Authors:  Andrea E Potash; Tanner J Wallen; Philip H Karp; Sarah Ernst; Thomas O Moninger; Nicholas D Gansemer; David A Stoltz; Joseph Zabner; Eugene H Chang
Journal:  Mol Ther       Date:  2013-03-19       Impact factor: 11.454

Review 10.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.